Search for European Projects

34 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalised medicine (MultipleMS)

Start date: Jan 1, 2017, End date: Dec 31, 2021,

The complex interactions between genetic and non-genetic factors produce heterogeneities in patients as reflected in the diversity of pathophysiology, clinical manifestations, response to therapies, disease development and progression. Yet, the full potential of personalized medicine entails biomarker-guided delivery of efficient therapies in stratified patient populations.MultipleMS will therefor ...
Read Project

 25

 FINISHED 

Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections (COMBACTE-MAGNET)

Start date: Jan 1, 2015, End date: Dec 31, 2021,

Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P. aeruginosa infection in critically ill patients and to develop new antibiotics for infections caused by Gram-negative bacte ...
Read Project

 44

 FINISHED 

European Gram Negative Antibacterial Engine (ENABLE)

Start date: Feb 1, 2014, End date: Jan 31, 2020,

The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens. There is a growing concern that the loss of therapeutic options will present us with a post-antibiotic era where present and future medical advances are negated. Resistant bacteria dramatically reduce the possibilities of treating infections effectively, a ...
Read Project

 42

 FINISHED 

Imaging the Force of Cancer (FORCE)

Start date: Jan 1, 2016, End date: Dec 31, 2019,

Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its significance, measuring metastatic potential as well as potential indicators of therapy efficacy remain unmet clinical challenges. Recently, it has been demonstrated in vitro, that aggressive metastatic cells pull on their surroundings suggesting that metastat ...
Read Project

 18

 FINISHED 

European Prevention of Alzheimer’s Dementia Consortium (EPAD)

Start date: Jan 1, 2015, End date: Dec 31, 2019,

Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions. To achieve this, EPAD will also provide the analytical infras ...
Read Project

 40

 FINISHED 

Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies (SPRINTT)

Start date: Jul 1, 2014, End date: Jun 30, 2019,

The current healthcare systems are built around the traditional paradigm of patients suffering from a single acute illness. They are therefore largely unprepared to face the increasing demands for health services arising from the expansion of an older population with specific medical needs related to multiple chronic disorders. As a consequence, the medical conditions of a large and growing seg ...
Read Project

 27

 FINISHED 

Intelligent Assessment of Pharmaceutical in the Environment (IPIE)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patients or when unused medicines are disposed of. As APIs are biologically active compounds concerns have been raised about the potential effects of APIs in the environment on human and environmental health. Over the past 15 years, a substantial amount of work has ...
Read Project

 29

 FINISHED 

Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of Drug Development and Therapy (AETIONOMY)

Start date: Jan 1, 2014, End date: Dec 31, 2018,

IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and (II) the focused application of this pipeline to derive clinically significant mechanistic taxonomies of neurodegenerativ ...
Read Project

 20

 FINISHED 

QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)

Start date: Sep 1, 2011, End date: Dec 31, 2017,

The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Read Project

 26

 FINISHED 

Molecular basis of the outer membrane permeability (TRANSLOCATION)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

Overcoming the barriers that the cell envelope and efflux pumps provide to Gram-negative bacteria is a major bottleneck in the discovery and development of new antibiotics. To respond to this Call we are extending our current network on antibiotic translocation and propose an ambitious project ranging from identification of novel resistance mechanisms in clinical bacterial isolates to crystallizat ...
Read Project

 28

 FINISHED 

Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT)

Start date: Nov 1, 2012, End date: Oct 31, 2017,

Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, miRNA, DARPins) with specificity for intracellular targets hold promise but await the advent of efficient delivery systems before their potential can be realised into ther ...
Read Project

 22

 FINISHED 

Kinetics for Drug Discovery (K4DD) (K4DD)

Start date: Nov 1, 2012, End date: Oct 31, 2017,

There is mounting evidence that the often ignored kinetic aspects of the interaction between a drug and its target are highly relevant for clinical success. This ignorance may be one of the reasons for the high attrition rates in drug discovery, as it has been analyzed that many recently marketed drugs had indeed improved kinetic profiles. This hindsight knowledge needs to be converted into data-d ...
Read Project

 21

 FINISHED 

Model-based preclinical development of anti-tuberculosis drug combinations (PREDICT-TB)

Start date: May 1, 2012, End date: Oct 30, 2017,

Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and combat multi-drug resistance. Although new agents are emerging, the path to registration of such regimens remains uncertain while capacity for pivotal trials is limited. Selection and optimization of drug combinations for development depends on preclinical sy ...
Read Project

 23

 FINISHED 

Oral biopharmaceutics tools (ORBITO)

Start date: Oct 1, 2012, End date: Sep 30, 2017,

The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will ...
Read Project

 28

 FINISHED 

DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE (DRIVE-AB)

Start date: Oct 1, 2014, End date: Sep 30, 2017,

Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a few pharmaceutical companies retain active antibacterial drug discovery programmes. While the elaboration of antibiotics with novel mechanisms of action is scientifically complex, the chief challenge is diminishing incentives. Pre-market regulatory requirements ...
Read Project

 27

 FINISHED 

Delivering European Translational Information & Knowledge Management Services (ETRIKS)

Start date: Oct 1, 2012, End date: Sep 30, 2017,

Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive translational research and are employing integrative analysis approaches to achieve their goals. Although a common KM platform for IMI projects was envisioned in the original IMI Strategic Research Agenda it has not yet been implemented. The lack of a common p ...
Read Project

 17

 FINISHED 

Recognising Adverse Drug Reactions (WEB-RADR)

Start date: Sep 1, 2014, End date: Aug 31, 2017,

WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the potential for the reporting of adverse drug reactions (ADRs) through mobile applications and the recognition of drug safety sign ...
Read Project

 20

 FINISHED 

New Oral Nanomedicines: Transporting Therapeutic Macromolecules across the Intestinal Barrier (TRANS-INT)

Start date: May 1, 2012, End date: Apr 30, 2017,

Despite the increasing number of macromolecules with potential impact in the treatment of devastating systemic diseases, these therapies have failed to deliver on their expectations because they cannot be administered in the fashion which is most cost efficient and has the highest patient compliance: the oral route. The availability of an oral form of administration could lead to a great improveme ...
Read Project

 20

 FINISHED 

Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)

Start date: Mar 1, 2012, End date: Feb 28, 2017,

The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Read Project

 39

 FINISHED 

Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI)

Start date: Feb 1, 2012, End date: Jan 31, 2017,

The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys ...
Read Project

 29

 FINISHED 

Infection biology training network: shaping the future of infectious diseases treatments (INBIONET)

Start date: Jan 1, 2013, End date: Dec 31, 2016,

...s internationally recognized in the fields of microbial pathogenesis, innate immunity and molecular recognition, an intensive research SME, Preclin Biosystems, a multinational pharmaceutical company, Sanofi-Aventis, and a technological park (ParcBit). INBIONET partners will embark on the analysis of bacteria, viruses and enteric parasites specified by various infection strategies to identify cellu ...
Read Project

 11

 FINISHED 

Incorporating real-life clinical data into drug development (GETREAL)

Start date: Oct 1, 2013, End date: Dec 31, 2016,

When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and efficacy of the medicine in a clinical trial setting. However, assessing the expected future value of the medicines when used in “real world” clinical practice requires additional information next to traditional (pre-authorisation) clinical trials. Regulatory, HTA ...
Read Project

 32

 FINISHED 

Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities (ETOX)

Start date: Jan 1, 2010, End date: Dec 31, 2016,

The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modell ...
Read Project

 30

 FINISHED 

European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)

Start date: Jan 1, 2010, End date: Nov 30, 2016,

Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Read Project

 34

 FINISHED 

Development of RApid Point-of-Care test Platforms for Infectious Diseases (RAPP-ID)

Start date: Apr 1, 2011, End date: Sep 30, 2016,

RAPP-ID (“Development of RApid Point-of-Care test Platforms for Infectious Diseases”) will develop a Point-of-Care Test (POCT) for rapid (hospital
Read Project

 20

 FINISHED 

European Medicines Research Training Network (EMTRAIN)

Start date: Oct 1, 2009, End date: Sep 30, 2016,

EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will establish a pan-European platform of excellence for education and training covering the whole life-cycle of medicines from basic research through clinical development to pharmaco-vigilance. It will underpin the successful delivery of the current and future IMI-f ...
Read Project

 32

 FINISHED 

European programme in Pharmacovigilance and Pharmacoepidemiology (EU2P)

Start date: Sep 1, 2009, End date: Jun 30, 2016,

The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia at the European level. It will give access to a harmonised training programme that gathers complementary specialized and eminent European partners. The Eu2P consortium consists of course providers with aproven record including the University of Bordeaux (Eu2P ...
Read Project

 24

 FINISHED 

Electronic Health Record systems for Clinical Research (EHR4CR)

Start date: Mar 1, 2011, End date: Feb 29, 2016,

Current medical needs, the growth of targeted therapies and personalized medicines, and escalating R&D costs result in formidable cost pressures on healthcare systems and the pharmaceutical industry. Clinical research is also growing in complexity, labour intensity and cost. There is a growing realization that the development and integration of Electronic Health Record systems (EHRs) for medical ...
Read Project

 37

 FINISHED 

Novel nanoparticles for drug delivery to the skin (NANODRUG)

Start date: Nov 1, 2011, End date: Oct 31, 2015,

The aim of the NANODRUG Network is to contribute to the defragmentation of the emerging field of nanomedicine by providing a unique training programme that will cover all different aspects ranging from NP synthesis and characterisation, drug delivery, molecular biology to nanotoxicology, preclinical studies, risk assessment and nanotechnology policy making. The NANODRUG training program is far sup ...
Read Project

 9

 FINISHED 

Understanding chronic pain and improving its treatment (EUROPAIN)

Start date: Oct 1, 2009, End date: Sep 30, 2015,

We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational research which will: 1) increase the understanding of chronic pain mechanisms; 2)facilitate the development of novel analgesic drugs; and 3) improve the treatment of chronic pain patients.Nineteen researchers drawn from the London Pain Consortium, the Danish Pain Re ...
Read Project

 29

 FINISHED 

SAFER AND FASTER EVIDENCE-BASED TRANSLATION (SAFE-T)

Start date: Jun 15, 2009, End date: Jun 14, 2015,

The public-private consortium composed of complementary SMEs, academic and clinical centers of excellence and EMEA as partner proposes SAFE-T (Safer And Easter Evidence-based Iranslation) project for the establishment of a biomarker (BM) qualification process and its validation in clinical biomarker studies designed for the translation, performance testing and eventual regulatory qualifIcatIon of ...
Read Project

 26

 FINISHED 

Pharmacoepidemiolocal Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT)

Start date: Sep 1, 2009, End date: Apr 30, 2015,

Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs. Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Age ...
Read Project

 36

 FINISHED 

Pharmaceutical Medicine Training Programme (PHARMATRAIN)

Start date: May 1, 2009, End date: Apr 30, 2014,

"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Read Project

 52

 FINISHED 

Light-based functional in vivo monitoring of diseases related enzymes (LIVIMODE)

Start date: Nov 1, 2009, End date: Apr 30, 2013,

"LIVIMODE aims to develop specific tools for non invasive in vivo imaging of disease related molecular events. Such tools are of high relevance for disease detection, staging, developing animal models of human disease, and evaluating novel therapies. We propose to use optical imaging, which is optimally suited for this task as it provides excellent sensitivity and allows visualizing molecular even ...
Read Project

 13